A Headache For Map: Levadex Gets “Complete Response” Letter From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency raised issues related to the chemistry, manufacturing and controls section of the dihydroergotamine NDA, as well as concerns stemming from inspection of a third-party manufacturing facility, the company says.
You may also be interested in...
Allergan’s Manufacturing Challenges Produce Second Levadex “Complete Response” Letter
FDA again cites inspection issues related to a third-party facility where the product canister for the migraine drug is manufactured, as well as the manufacturing process itself; Allergan says it recently completed an acquisition of that third-party firm, thereby bringing the inhaled treatment’s manufacturing in-house.
Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
While Allergan plans to diversify its portfolio in migraine by acquiring partner MAP and its candidate for acute migraine, NuPathe seeks a partner for a triptan patch product expected to avoid the nausea suffered by many migraine patients.
Allergan Buys MAP To Chart Migraine Franchise Growth
Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.